Molecular Oncology

EDITORIAL BOARD

J. Celis (Copenhagen, Denmark)  
Editor-in-Chief
U. Ringborg (Solna, Sweden)
J. E. Visvader (Parkville, Victoria, Australia)
Senior Associate Editors
H. Allgayer (Heidelberg, Germany)
M. Boutros (Heidelberg, Germany)
G. Calin (Houston, Texas, USA)
G. Melino (Leicester, UK)
M. Nilbert (Copenhagen, Denmark)
K. Pantel (Hamburg, Germany)
Section Editors
J. Moreira (Copenhagen, Denmark)
Reviews Editor
R. Aebersold (Zurich, Switzerland)
K. Alitalo (Helsinki, Finland)
G. Almouzni (Paris, France)
M. Barbacid (Madrid, Spain)
A. Bardelli (Torino, Italy)
J. Bartek (Copenhagen, Denmark)
S.B. Baylin (Baltimore, MD, USA)
R. Bernards (Amsterdam, The Netherlands)
A.J.M. Berns (Amsterdam, The Netherlands)
M. Bissell (Berkeley, CA, USA)
C. Blanpain (Brussels, Belgium)
M. Boutros (Heidelberg, Germany)
A. Børresen-Dale (Oslo, Norway)
C. Caldas (Cambridge, UK)
F. Carneiro (Porto, Portugal)
E. P. Diamandis (Toronto, ON, Canada)
P.P. Di Fiore (Milan, Italy)
L.M. Ellis (Houston, TX, USA)
M. Esteller (Barcelona, Spain)
S.H. Friend (Seattle, WA, USA)
T.R. Golub (Boston, MA, USA)
H.B. Grossman (Houston, TX, USA)
N. Harbeck (München, Germany)
D.F. Hayes (Ann Arbor, MI, USA)
C.-H. Heldin (Uppsala, Sweden)
Á. Helland (Oslo, Norway)
T. Helleday (Stockholm, Sweden)
H. Hricak (New York, NY, USA)
T. Hunter (La Jolla, CA, USA)
J. Ivaska (Laskut, Finland)
O. Kallioniemi (Turku, Finland)
G. Kroemer (Villejeuf, France)
O.C. Lingjaerde (Oslo, Norway)
E. Liu (Singapore, Singapore)
C. Lord (London, UK)
T. W. Mak (Toronto, ON, Canada)
R. Marais (London, UK)
E. Mardis (St. Louis, MO, USA)
J. Massagué (New York, NY, USA)
J. Mendelsohn (Houston, TX, USA)
G.B. Mills (Houston, TX, USA)
M. Oren (Rehovot, Israel)
K. Pantel (Hamburg, Germany)
P. Pandalfo (Boston, MA, USA)
D. Peeper (Amsterdam, The Netherlands)
M. Piccart (Brussels, Belgium)
J.W. Pollard (Edinburgh, UK)
D.F. Ransohoff (Chapel Hill, NC, USA)
H. Sasano (Sendai, Japan)
J. Seone (Barcelona, Spain)
P. Spellman (Portland, OR, USA)
J. Taberou (Barcelona, Spain)
D. Tarin (La Jolla, CA, USA)
M.L. Tykocinski (Philadelphia, PA, USA)
N. Urban (Seattle, WA, USA)
K. H. Vousden (Glasgow, UK)
A. Wellstein (Washington, DC, USA)
P. Workman (Sutton, UK)
H.-M. Yang (Beijing, China)
Y. Yarden (Rehovot, Israel)
T. Yeatman (Tampa, FL, USA)
Q. Zhan (Beijing, China)
L. Zitvogel (Villejeuf, France)

EDITORIAL OFFICE

The Danish Cancer Society - Krafteens Bekæmpelse, Copenhagen, DK-2100, Denmark
Email: Molonc@cancer.dk

PRODUCTION OFFICE

Marion Laws (Senior Production Editor)
John Wiley & Sons Ltd, 9600 Garsington Road, Oxford OX4 2DQ, UK

Cover Illustration
Additive therapeutic efficacy of CD47mAb and doxorubicin therapy: CD47mAb blocks a ‘don’t eat me’ signal (CD47) on cancer cells and doxorubicin causes expression of an ‘eat me’ signal (calreticulin) on cancer cells, leading to highly effective macrophage phagocytosis. Image created by Jim Strommer, Stanford University. See article by Mohanty et al. (pp 2049–2061).

Online ISSN: 1878-0261

This journal is Open Access; all articles will be immediately and permanently free for everyone to read and download. Permitted reuse is defined by a Creative Commons user license:
Creative Commons Attribution (CC BY)
http://creativecommons.org/licenses/by/4.0/

Disclaimer The Publisher and Editors cannot be held responsible for errors or any consequences arising from the use of information contained in this journal; the views and opinions expressed do not necessarily reflect those of the Publisher and Editors, neither does the publication of advertisements constitute any endorsements by the Publisher and Editors of the products advertised. Wiley Open Access articles posted to repositories or websites are without warranty from Wiley of any kind, either express or implied, including, but not limited to, warranties of merchantability, fitness for a particular purpose, or non-infringement. To the fullest extent permitted by law Wiley disclaims all liability for any loss or damage arising out of, or in connection with, the use of or inability to use the content.